Results 151 to 160 of about 131,984 (259)

Is PPR Epidemiological Research Addressing Global Eradication Priorities? A Scoping Review (2015-2025). [PDF]

Viruses
Alemayehu G, Knight-Jones T.
europepmc   +1 more source

New concepts in disease eradication

Veterinary Record, 1980
openaire   +2 more sources

Evaluating the (comparative) safety profile of the novel oral polio vaccine type 2 using individual case safety reports in VigiBase

British Journal of Clinical Pharmacology, EarlyView.
Aim Novel oral polio vaccine type 2 (nOPV2) was used under the WHO emergency use listing for circulating vaccine‐derived polio virus (cVDPV) outbreaks from 2021 to 2023. We assessed nOPV2 adverse events following immunization (AEFIs) and compared its safety profile to other vaccines using VigiBase.
Comfort Kunak Ogar, Malede Mequanent Sisay, Leonardo Roque‐Pereira, Christine Leopold, Patrick C. Souverein, Aukje K. Mantel‐Teeuwisse, Marie L. De Bruin   +6 more
wiley   +1 more source

From screening to surveillance: integrated prevention of <i>Helicobacter pylori</i>-associated gastric cancer in the Asia-Pacific region. [PDF]

Lancet Reg Health West Pac
Yoon J, Oh DY.
europepmc   +1 more source

Relationship between continuous infusion meropenem PK/PD target attainment and C‐reactive protein dynamics in onco‐haematologic patients with febrile neutropenia

British Journal of Clinical Pharmacology, EarlyView.
Aim Meropenem is a second‐line antimicrobial agent in the treatment of febrile neutropenia in onco‐haematological patients. A population pharmacokinetic/pharmacodynamic (PK/PD) analysis for assessing the relationship between meropenem exposure and C‐reactive protein (C‐RP) over time was conducted.
Chun Liu, Pier Giorgio Cojutti, J. G. Coen van Hasselt, Michele Bartoletti, Maddalena Giannella, Pierluigi Zinzani, Pierluigi Viale, Federico Pea   +7 more
wiley   +1 more source

Harnessing ferroptosis from multilayer defense networks to nanoplatforms for specific cancer therapy

BMEMat, EarlyView.
Nanomaterials target metabolically‐regulated ferroptosis for cancer therapy. Iron‐based or alternative nanoplatforms integrate ferroptosis with chemotherapy, immunotherapy, or radiotherapy. They enable stimulus‐responsive therapies (photothermal, photodynamic, sonodynamic) activated by near‐infrared, light, or ultrasound, achieving potent synergistic ...
Xinyue Xu, Xuejian Wang, Wenyan Jiang, Wan Hairul Anuar Kamaruddin, Chunyan Fang, Pengfei Zhang   +5 more
wiley   +1 more source

Comparative effectiveness of genotype-guided and empirical bismuth-containing quadruple therapy for <i>Helicobacter pylori</i> eradication: a retrospective study. [PDF]

Front Pharmacol
Wang P, Yang M, Zhao X, Ding H, Cheng J.
europepmc   +1 more source

Tackling cancer stemness with nanotechnology in the era of precision medicine

BMEMat, EarlyView.
Precise customization of nanoparticles (NPs) enables active targeting of cancer stem cells (CSCs), thereby improving drug delivery and therapeutic efficacy. NP‐based probing enhances CSC detection through imaging and liquid biopsy, whereas diverse therapeutic payloads improve therapeutic outcomes.
Shaolei Guo, Shun Yao, Lihui Meng, Chunyuan Chen, Yuechu Lucinda Lu, Rong Lu, Kashif Rafiq Zahid, Umar Raza, Qingzhi Wu, Wenli Chen   +9 more
wiley   +1 more source

Efficacy and safety of live combined Bacillus subtilis and Enterococcus faecium in patients with Helicobacter pylori infection: A meta-analysis of randomized controlled trials. [PDF]

Clinics (Sao Paulo)
Yang C, Lu B, Zhang C, Wang A, Chen Y.
europepmc   +1 more source

Dual‐targeted nanomedicine delivering doxorubicin and nitric oxide for tumor immunomodulation and synergistic therapy

BMEMat, EarlyView.
The mechanism of HA‐DS@PLGA nanoparticles co‐delivering DOX and SNAP (an NO donor) to suppress tumor growth, remodel the tumor microenvironment, and enhance antitumor immune responses for effective combinatorial cancer therapy. Abstract Cancer therapeutic efficacy is significantly influenced by tumor immunosuppressive environment possibly induced by ...
Xingzhou Peng, Wei Chen, Shuyu Li, Xiaomin Ma, Yanfeng Dai, Yan Wang, Changqiang Xie, Yazhe Xiao, Hesong Han, Yumiao Zhang, Junjie Wang   +10 more
wiley   +1 more source